OncoMatch/Clinical Trials/NCT07805954
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
Official title: A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
Is NCT07805954 recruiting? Yes, currently enrolling (Oct 2026). This Phase 3 trial studies multiple treatments including daraxonrasib and gemcitabine for pancreatic cancer.
Treatment: daraxonrasib · gemcitabine · nab-paclitaxel · zoldonrasib — The purpose of this study is to evaluate the efficacy of combination therapy with two investigational RAS(ON) inhibitors (daraxonrasib and zoldonrasib) compared to chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Pancreatic Cancer
Biomarker criteria
Required: KRAS g12d
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: MAPK-pathway targeted therapy in the metastatic setting
Prior treatment with MAPK-pathway targeted therapy or administration of RAS-targeted vaccine in the metastatic setting
Cannot have received: RAS-targeted vaccine in the metastatic setting
Prior treatment with MAPK-pathway targeted therapy or administration of RAS-targeted vaccine in the metastatic setting
Lab requirements
Blood counts
adequate organ function (bone marrow, liver, kidney, coagulation)
Kidney function
adequate organ function (bone marrow, liver, kidney, coagulation)
Liver function
adequate organ function (bone marrow, liver, kidney, coagulation)
Adequate organ function (bone marrow, liver, kidney, coagulation)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Moffitt Cancer Center · Tampa, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07805954 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require KRAS?
Yes, KRAS g12d is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify